GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The invasive lineage creates cytotrophoblasts that are essential in the process of implantation and forming a fully functional placenta. An undifferentiated cytotrophoblastic stem cell will differentiate into an extravillous cytotrophoblast intermediate and then into an interstitial cytotrophoblast. An interstitial cytotrophoblast may then further differentiate into an endovascular cytotrophoblast or form a syncytium.
Iodine-131 (131I) is a beta-emitting isotope with a half-life of 8.0249 days, and comparatively energetic (0.61 MeV) beta radiation, which penetrates 0.6 to 2.0 mm from the site of uptake. This beta radiation can be used for the destruction of thyroid nodules or hyperfunctioning thyroid tissue and for elimination of remaining thyroid tissue after surgery for the treatment of Graves' disease. The purpose of this therapy, which was first explored by Dr. Saul Hertz in 1941, is to destroy thyroid tissue that could not be removed surgically. In this procedure, 131I is administered either intravenously or orally following a diagnostic scan. This procedure may also be used, with higher doses of radio-iodine, to treat patients with thyroid cancer. The 131I is taken up into thyroid tissue and concentrated there. The beta particles emitted by the radioisotope destroys the associated thyroid tissue with little damage to surrounding tissues (more than 2.0 mm from the tissues absorbing the iodine). Due to similar destruction, 131I is the iodine radioisotope used in other water-soluble iodine-labeled radiopharmaceuticals (such as MIBG) used therapeutically to destroy tissues. The high energy beta radiation (up to 606 keV) from 131I causes it to be the most carcinogenic of the iodine isotopes.
=== Niche uses === Ethylene oxide is used as a fungicide and as an accelerator of maturation of tobacco leaves. Ethylene oxide is also used as a main component of thermobaric weapons (fuel-air explosives).
Sources: en.wikipedia.org
=== Class I === Class I hydrophobins are characterised by having a quite diverse amino acid sequence between different types (with exception of the conserved cysteine residues), and compared to class II, they have long, varied inter-cysteine spacing. They form rodlets which have been identified as functional amyloids due to their amyloid-like characteristics as seen in X-ray diffraction studies and confirmed by their capacity to bind to amyloid-specific dyes such as Congo red and Thioflavin T. The formation of rodlets involves conformational changes that lead to formation of an extremely robust β-sheet structure that can only be depolymerised by treatment with strong acids. The rodlets can spontaneously form ordered monolayers by lateral assembly, displaying a regular fibrillary morphology on hydrophobic:hydrophilic interfaces. The most well characterised class I hydrophobin is EAS, which coats the spores of the fungus Neurospora crassa, followed by characterisation of DewA from Aspergillus nidulans.
=== Other subsidiaries === Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines. In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company. The same year, Biocon started NeoBiocon FZ LLC, a research and marketing pharmaceutical company based in Abu Dhabi. In 2023, Biocon purchased Biofusion Therapeutics Limited.
In June 2022, during the annual OECD Ministerial Council Meeting, the Roadmaps for the Accession to the OECD Convention for Brazil, Bulgaria, Croatia, Peru and Romania were adopted. In March 2024, the Roadmaps for the Accession to the OECD were adopted with Argentina and Indonesia, and in July 2024, also with Thailand.
A cofactor is a non-protein chemical compound or metallic ion that is required for an enzyme's role as a catalyst. Cofactors can be considered "helper molecules" that assist in biochemical transformations. The rates at which these happen are characterized in an area of study called enzyme kinetics. Cofactors typically differ from ligands in that they often derive their function by remaining bound. Cofactors can be classified into two types: inorganic ions and complex organic molecules called coenzymes. Coenzymes are mainly derived from vitamins and other organic essential nutrients in small amounts (some definitions limit the use of the term "cofactor" for inorganic substances; both types are included here). Coenzymes are further divided into two types. The first is called a "prosthetic group", which consists of a coenzyme that is tightly (or even covalently and, therefore, permanently) bound to a protein. The second type of coenzymes are called "cosubstrates", and are transiently bound to the protein. Cosubstrates may be released from a protein at some point, and then rebind later. Both prosthetic groups and cosubstrates have the same function, which is to facilitate the reaction of enzymes and proteins. An inactive enzyme without the cofactor is called an apoenzyme, while the complete enzyme with cofactor is called a holoenzyme.
Sources: en.wikipedia.org
=== Clinical relevance of sulcular epithelium in periodontal surgery === It was historically practised that the sulcular epithelium was removed during periodontal surgery. It was thought that the diseased ‘pocket epithelium’ could prevent re-attachment of healthy connective tissue and new periodontal ligament to the root surface. Furthermore, the ‘pocket epithelium’ which includes the sulcular epithelium was considered as a pathologic tissue lining containing bacteria and inflammatory cells which could result in periodontal destruction. Nonetheless, a study has demonstrated that its removal during flap surgery did not worsen attachment gain, pocket reduction or the healing outcome. In fact, its removal could lead to gingiva recession, a poorer esthetic outcome and increased root sensitivity or caries risk. Hence, it was concluded that the sulcular epithelium plays a protective role and shouldn’t be routinely removed unlike older periodontal techniques which necessitate it.
Deborah Ann Dingell ( DING-gəl; née Insley; November 23, 1953) is an American politician serving as a U.S. representative from Michigan since 2015, representing the state's 6th congressional district since 2023. A member of the Democratic Party, she succeeded her late husband, John Dingell, who was the longest-serving member of Congress in U.S. history. Dingell is active in several organizations in Michigan and Washington, D.C., and serves on a number of boards. She is a founder and past chair of the National Women's Health Resource Center and the Children's Inn at the National Institutes of Health (NIH). She is also a member of the board of directors for Vital Voices Global Partnership. She is a 1975 graduate of the Edmund A. Walsh School of Foreign Service at Georgetown University. She worked as a consultant to the American Automobile Policy Council. She was a superdelegate for the 2012 Democratic National Convention in Charlotte, North Carolina.
== Description == The fool's mushroom is pure white, all the way to the gills and the stipe. This fungus, like many but not all amanitas, has a volva. The fool's mushroom's cap is 5–10 centimetres (2–4 inches) wide, and is about the same height. This mushroom's lamellae are free and white, and the volva is bag-like and large. Its annulus is white and membranous, and A. verna react yellow with 20% potassium hydroxide solution, unlike its relative Amanita phalloides var. alba while Amanita virosa gets an orange-yellow reaction. The mushroom's spores are smooth and elliptical.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.